Cor Vasa 2025, 67(4):469-482 | DOI: 10.33678/cor.2025.086

(Sudden cardiac death in hypertrophic cardiomyopathy)

Michael Jenąovský, Veronika Puchnerová, Petr Oą»ádal, Jiří Bonaventura
Kardiologická klinika, 2. lékařská fakulta Univerzity Karlovy a Fakultnî nemocnice v Motole, Praha, Česká republika

Sudden cardiac death (SCD) is the most feared complication of hypertrophic cardiomyopathy (HCM) and can be the first and only manifestation of HCM. Our review focuses on the evolution of epidemiology and pathophysiology of SCD in HCM patients, with an emphasis on current risk stratification options for the primary prevention of SCD in HCM. It provides a detailed overview of the individual risk factors of SCD, the benefits and potential risks of physical activity, as well as the benefits and complications of implantable cardioverter-defibrillators in patients with HCM.

Keywords: Hypertrophic cardiomyopathy, Implantable cardioverter- -defibrillator, Risk stratification, Sudden cardiac death

Received: May 28, 2025; Revised: July 9, 2025; Accepted: August 1, 2025; Prepublished online: June 2, 2012; Published: October 6, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jenąovský M, Puchnerová V, Oą»ádal P, Bonaventura J. (Sudden cardiac death in hypertrophic cardiomyopathy). Cor Vasa. 2025;67(4):469-482. doi: 10.33678/cor.2025.086.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Maron BJ, Desai MY, Nishimura RA, et al. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 2022;79:390-414. Go to original source... Go to PubMed...
    2. Maron MS, Rowin EJ, Maron BJ. The Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. Am J Cardiol 2024;212:S64-S76. Go to original source... Go to PubMed...
    3. Braunwald E, Lambrew CT, Rockoff SD, et al. Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients. Circulation 1964;29(Suppl. 4):3-119. Go to original source... Go to PubMed...
    4. Abdelfattah OM, Martinez M, Sayed A, et al. Temporal and Global Trends of the Incidence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol 2022;8:1417-1427. Go to original source... Go to PubMed...
    5. Couper K, Putt O, Field R, et al. Incidence of sudden cardiac death in the young: a systematic review. BMJ Open 2020;10:e040815. Go to original source... Go to PubMed...
    6. D'Ascenzi F, Valentini F, Pistoresi S, et al. Causes of sudden cardiac death in young athletes and non-athletes: systematic review and meta-analysis: Sudden cardiac death in the young. Trends Cardiovasc Med 2022;32:299-308. Go to original source... Go to PubMed...
    7. Risgaard B, Winkel BG, Jabbari R, et al. Burden of sudden cardiac death in persons aged 1 to 49 years nationwide study in Denmark. Circ Arrhythm Electrophysiol 2014;7:205-211. Go to original source... Go to PubMed...
    8. Francia P, Falasconi G, Penela D, et al. Scar architecture affects the electrophysiological characteristics of induced ventricular arrhythmias in hypertrophic cardiomyopathy. EP Europace 2024;26:euae050. Go to original source... Go to PubMed...
    9. Fluechter S, Kuschyk J, Wolpert C, et al. Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2010;12:30. Go to original source... Go to PubMed...
    10. Durdil V. Ventricular arrhythmias and sudden death in hypertrophic cardiomyopathy. Cor Vasa 2010;52:441-446. Go to original source...
    11. Schumacher B, Gietzen FH, Neuser H, et al. Electrophysiological characteristics of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy and moderate to severe symptoms. Circulation 2005;112:2096-2101. Go to original source... Go to PubMed...
    12. Perez-Alday EA, Haq KT, German DM, et al. Mechanisms of Arrhythmogenicity in Hypertrophic Cardiomyopathy: Insight From Non-invasive Electrocardiographic Imaging. Front Physiol 2020;11:496978. Go to original source... Go to PubMed...
    13. Segev A, Wasserstrum Y, Arad M, et al. Ventricular arrhythmias in patients with hypertrophic cardiomyopathy: Prevalence, distribution, predictors, and outcome. Heart Rhythm 2023;20:1385-1392. Go to original source... Go to PubMed...
    14. Link MS, Bockstall K, Weinstock J, et al. Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications. J Cardiovasc Electrophysiol 2017;28:531-537. Go to original source... Go to PubMed...
    15. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J 2023;44:3503-3626. Go to original source... Go to PubMed...
    16. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2024;149:e1239-e1311. Go to original source... Go to PubMed...
    17. Zeppenfeld K, Tfelt-Hansen J, De Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the Task Force for the Management of Patients with Ventricular Arrhythmias and the Preventiono Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2022;43:3997-4126. Go to original source... Go to PubMed...
    18. Rowin EJ, Das G, Madias C, et al. Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy. Heart Rhythm 2025;22:1696-1704. Go to original source... Go to PubMed...
    19. Maron MS, Rowin E, Spirito P, et al. Differing strategies for sudden death prevention in hypertrophic cardiomyopathy. Heart 2023;109:589-594. Go to original source... Go to PubMed...
    20. Bonaventura J, Jensovsky M, Puchnerova V, et al. Effectiveness of contemporary risk stratification in patients with hypertrophic cardiomyopathy: a pilot study. Eur Heart J 2024;45(Suppl. 1). Go to original source...
    21. Bonaventura J, Maron BJ, Berul CI, et al. Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity. Heart Rhythm 2023;4:506-516. Go to original source... Go to PubMed...
    22. Miron A, Lafreniere-Roula M, Steve Fan CP, et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation. 2020;142:217-229. Go to original source... Go to PubMed...
    23. Norrish G, Qu C, Field E, et al. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. Eur J Prev Cardiol 2022;29:678-686. Go to original source... Go to PubMed...
    24. O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J 2014;35:2010-2020. Go to original source... Go to PubMed...
    25. Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009;119:1703-1710. Go to original source... Go to PubMed...
    26. Rowin EJ, Burrows A, Madias C, et al. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants. Circ Arrhythm Electrophysiol 2020;13(10):E008123. Go to original source... Go to PubMed...
    27. Maron BJ, Spirito P, Shen WK, et al. Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JAMA 2007;298:405-412. Go to original source... Go to PubMed...
    28. Maron BJ, Rowin EJ, Casey SA, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy ≥60 years of age. Circulation 2013;127(5):585-593. Go to original source... Go to PubMed...
    29. Zampieri M, Salvi S, Fumagalli C, et al. Clinical scenarios of hypertrophic cardiomyopathy-related mortality: Relevance of age and stage of disease at presentation. Int J Cardiol 2023;374:65-72. Go to original source... Go to PubMed...
    30. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:873-879. Go to original source... Go to PubMed...
    31. Maron BJ, Casey SA, Hurrell DG, et al. Relation of left ventricular thickness to age and gender in hypertrophic cardiomyopathy. Am J Cardiol 2003;91:1195-1198. Go to original source... Go to PubMed...
    32. Bonaventura J, Rowin EJ, Maron MS, et al. Is Hypertrophic Cardiomyopathy Always a Familial and Inherited Disease? J Am Heart Assoc 2023;12:28974. Go to original source... Go to PubMed...
    33. Bonaventura J, Polakova E, Vejtasova V, et al. Genetic Testing in Patients with Hypertrophic Cardiomyopathy. Int J Mol Sci 2021;22:10401. Go to original source... Go to PubMed...
    34. Bonaventura J, Rowin EJ, Chan RH, et al. Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy. J Am Heart Assoc 2024;13:33565. Go to original source... Go to PubMed...
    35. Butters A, Lakdawala NK, Ingles J. Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment. Curr Heart Fail Rep 2021;18:264-273. Go to original source... Go to PubMed...
    36. Hinojar R, Zamorano JL, Fernández-Méndez MA, et al. Prognostic value of left atrial function by cardiovascular magnetic resonance feature tracking in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging 2019;35:1055-1065. Go to original source... Go to PubMed...
    37. Olivotto I, Gistri R, Petrone P, et al. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;41:315-321. Go to original source... Go to PubMed...
    38. Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation 1998;97:461-466. Go to original source... Go to PubMed...
    39. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-2218. Go to original source... Go to PubMed...
    40. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-1785. Go to original source... Go to PubMed...
    41. Elliott PM, Gimeno Blanes JR, Mahon NG, et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001;357:420-424. Go to original source... Go to PubMed...
    42. O'Mahony C, Jichi F, Monserrat L, et al. Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol 2016;9:e003818. Go to original source... Go to PubMed...
    43. Louie EK, Maron BJ. Hypertrophic cardiomyopathy with extreme increase in left ventricular wall thickness: functional and morphologic features and clinical significance. J Am Coll Cardiol 1986;8:57-65. Go to original source... Go to PubMed...
    44. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-2218. Go to original source... Go to PubMed...
    45. Captur G, Manisty CH, Raman B, et al. Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy: Biomarker Variability and its Impact on Clinical Care. JACC Cardiovasc Imaging 2021;14:2123-2134. Go to original source... Go to PubMed...
    46. Tower-Rader A, Kramer CM, Neubauer S, et al. Multimodality Imaging in Hypertrophic Cardiomyopathy for Risk Stratification. Circ Cardiovasc Imaging 2020;13:E009026. Go to original source... Go to PubMed...
    47. Debonnaire P, Joyce E, Hiemstra Y, et al. Left Atrial Size and Function in Hypertrophic Cardiomyopathy Patients and Risk of New-Onset Atrial Fibrillation. Circ Arrhythm Electrophysiol 2017;10:e004052. Go to original source... Go to PubMed...
    48. Minami Y, Haruki S, Yashiro B, et al. Enlarged left atrium and sudden death risk in hypertrophic cardiomyopathy patients with or without atrial fibrillation. J Cardiol 2016;68:478-484. Go to original source... Go to PubMed...
    49. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-271. Go to original source... Go to PubMed...
    50. Mills H, Espersen K, Jurlander R, et al. Prevention of sudden cardiac death in hypertrophic cardiomyopathy: Risk assessment using left atrial diameter predicted from left atrial volume. Clin Cardiol 2020;43:581. Go to original source... Go to PubMed...
    51. Bhopalwala H, Dewaswala N, Liu S, et al. Conversion of left atrial volume to diameter for automated estimation of sudden cardiac death risk in hypertrophic cardiomyopathy. Echocardiography 2021;38:183-188. Go to original source... Go to PubMed...
    52. Hiemstra YL, Debonnaire P, Bootsma M, et al. Global Longitudinal Strain and Left Atrial Volume Index Provide Incremental Prognostic Value in Patients with Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging 2017;10:1-9. Go to original source... Go to PubMed...
    53. Debonnaire P, Thijssen J, Leong DP, et al. Global longitudinal strain and left atrial volume index improve prediction of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy patients. Int J Cardiovasc Imaging 2014;30:549-558. Go to original source... Go to PubMed...
    54. Hinojar R, Zamorano JL, Fernández-Méndez MA, et al. Prognostic value of left atrial function by cardiovascular magnetic resonance feature tracking in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging 2019;35:1055-1065. Go to original source... Go to PubMed...
    55. Tian D, Zhang JY, He YF, et al. Predictive value of left atrial strain analysis in adverse clinical events in patients with hypertrophic cardiomyopathy: a CMR study. BMC Cardiovasc Disord 2023;23:1-15. Go to original source... Go to PubMed...
    56. Correia E, Rodrigues B, Santos LF, et al. Longitudinal left ventricular strain in hypertrophic cardiomyopathy: correlation with nonsustained ventricular tachycardia. Echocardiography. 2011;28:709-714. Go to original source... Go to PubMed...
    57. Maron BJ, Bonow RO, Salberg L, et al. The First Patient Clinically Diagnosed With Hypertrophic Cardiomyopathy. Am J Cardiol 2008;102:1418-1420. Go to original source... Go to PubMed...
    58. Maron MS. Family History of Sudden Death Should Be a Primary Indication for Implantable Cardioverter Defibrillator in Hypertrophic Cardiomyopathy. Can J Cardiol 2015;31:1402-1406. Go to original source... Go to PubMed...
    59. Weissler-Snir A, Adler A, Williams L, et al. Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge. Eur Heart J 2017;38:1728-1737. Go to original source... Go to PubMed...
    60. Christiaans I, Van Engelen K, Van Langen IM, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. EP Europace 2010;12:313-321. Go to original source... Go to PubMed...
    61. Bos JM, Maron BJ, Ackerman MJ, et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol 2010;106:1481-1486. Go to original source... Go to PubMed...
    62. O'Mahony C, Elliott P, McKenna W. Sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 2013;6:443-451. Go to original source... Go to PubMed...
    63. Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Curr Opin Cardiol 2022;37:15-21. Go to original source... Go to PubMed...
    64. Elliott PM, Gimeno JR, Tomé MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933-1941. Go to original source... Go to PubMed...
    65. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:465-466. Go to original source... Go to PubMed...
    66. He Y, Ma H, Sun N, et al. Prognosis of Patients with Hypertrophic Obstructive Cardiomyopathy: A Multicenter Cohort Study with Data-Driven Propensity Score Matching Analysis. Rev Cardiovasc Med 2023;24:267. Go to original source... Go to PubMed...
    67. Desai MY, Smedira NG, Dhillon A, et al. Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: Potential for refinement of current criteria. J Thorac Cardiovasc Surg 2018;156:750.e3-759.e3. Go to original source... Go to PubMed...
    68. Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:470-476. Go to original source... Go to PubMed...
    69. Jensen MK, Prinz C, Horstkotte D, et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart 2013;99:1012-1017. Go to original source... Go to PubMed...
    70. Cuoco FA, Spencer WH, Fernandes VL, et al. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol 2008;52:1718-1723. Go to original source... Go to PubMed...
    71. Liebregts M, Faber L, Jensen MK, et al. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation. Europace 2018;20(FI2):f198-f203. Go to original source... Go to PubMed...
    72. Veselka J, Liebregts M, Cooper R, et al. Prediction of Sudden Cardiac Arrest After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: ASA-SCARRE Risk Score. Am J Cardiol 2022;184:120-126. Go to original source... Go to PubMed...
    73. Liebregts M, Vriesendorp PA, Mahmoodi BK, et al. A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy. JACC Heart Fail 2015;3:896-905. Go to original source... Go to PubMed...
    74. Vriesendorp PA, Liebregts M, Steggerda RC, et al. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Fail 2014;2:630-636. Go to original source... Go to PubMed...
    75. Singh K, Qutub M, Carson K, et al. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv 2016;88:107-115. Go to original source... Go to PubMed...
    76. Williams L, Frenneaux M. Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment. EP Europace 2007;9:817-822. Go to original source... Go to PubMed...
    77. Mascia G, Crotti L, Groppelli A, et al. Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis. Int J Cardiol 2022;357:88-94. Go to original source... Go to PubMed...
    78. Sediva H, Hnat T, Bonaventura J, et al. Head-Up Tilt Test in Risk Stratification of Patients with Hypertrophic Cardiomyopathy. Int J Angiol 2019;28:245. Go to original source... Go to PubMed...
    79. Brignole M, Cecchi F, Anastasakis A, et al. Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management. Int J Cardiol 2023;370:330-337. Go to original source... Go to PubMed...
    80. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987-2991. Go to original source... Go to PubMed...
    81. Nagata M, Shimizu M, Ino H, et al. Hemodynamic changes and prognosis in patients with hypertrophic cardiomyopathy and abnormal blood pressure responses during exercise. Clin Cardiol 2003;26:71-76. Go to original source... Go to PubMed...
    82. Rodrigues T, Raposo SC, Brito D, et al. Prognostic relevance of exercise testing in hypertrophic cardiomyopathy. A systematic review. Int J Cardiol 2021;339:83-92. Go to original source... Go to PubMed...
    83. Gimeno JR, Tomé-Esteban M, Lofiego C, et al. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009;30:2599-2605. Go to original source... Go to PubMed...
    84. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:873-879. Go to original source... Go to PubMed...
    85. Wang W, Lian Z, Rowin EJ, et al. Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 2017;10:e004604. Go to original source... Go to PubMed...
    86. Maron MS, Rowin EJ, Wessler BS, et al. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol 2019;4:644-657. Go to original source... Go to PubMed...
    87. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006;114:216-225. Go to original source... Go to PubMed...
    88. Rowin EJ, Maron BJ, Carrick RT, et al. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. J Am Coll Cardiol 2020;75:3033-3043. Go to original source... Go to PubMed...
    89. Kawarai H, Kajimoto K, Minami Y, et al. Risk of sudden death in end-stage hypertrophic cardiomyopathy. J Card Fail 2011;17:459-464. Go to original source... Go to PubMed...
    90. Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol 2017;69:761-773. Go to original source... Go to PubMed...
    91. Habib M, Hoss S, Adler A, et al. Apical Aneurysm Development in Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging 2023;16:E015555. Go to original source... Go to PubMed...
    92. Papanastasiou CA, Zegkos T, Karamitsos TD, et al. Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis. Int J Cardiol 2021;332:127-132. Go to original source... Go to PubMed...
    93. Garg J, Kewcharoen J, Shah K, et al. Clinical outcomes of radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2023;34:219-224. Go to original source... Go to PubMed...
    94. Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008;118:1541-1549. Go to original source... Go to PubMed...
    95. Lee DZJ, Montazeri M, Bataiosu R, et al. Clinical Characteristics and Prognostic Importance of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging 2022;15:1696-1711. Go to original source... Go to PubMed...
    96. Rowin E, Lee D, Tower-Rader A, et al. Sudeden Death Risk Among Hypertrophic Cardiomyopathy Patients With Left Ventricular Apical Aneurysmy: Does Size Metter? J Am Coll Cardiol 2025;85:1251. Go to original source...
    97. Moon JCC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;43:2260-2264. Go to original source... Go to PubMed...
    98. Moravsky G, Ofek E, Rakowski H, et al. Myocardial Fibrosis in Hypertrophic Cardiomyopathy: Accurate Reflection of Histopathological Findings by CMR. JACC Cardiovasc Imaging 2013;6:587-596. Go to original source... Go to PubMed...
    99. Weng Z, Yao J, Chan RH, et al. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis. JACC Cardiovasc Imaging 2016;9:1392-1402. Go to original source... Go to PubMed...
    100. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1369-1374. Go to original source... Go to PubMed...
    101. Ismail TF, Jabbour A, Gulati A, et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart 2014;100:1851-1858. Go to original source... Go to PubMed...
    102. Kiaos A, Daskalopoulos GN, Kamperidis V, et al. Quantitative Late Gadolinium Enhancement Cardiac Magnetic Resonance and Sudden Death in Hypertrophic Cardiomyopathy: A Meta-Analysis. JACC Cardiovasc Imaging 2024;17:489-497. Go to original source... Go to PubMed...
    103. Mentias A, Raeisi-Giglou P, Smedira NG, et al. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function. J Am Coll Cardiol 2018;72:857-870. Go to original source... Go to PubMed...
    104. Chan RH, Maron BJ, Olivotto I, et al. Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 2015;116:436-441. Go to original source... Go to PubMed...
    105. Liu J, Zhao S, Yu S, et al. Patterns of Replacement Fibrosis in Hypertrophic Cardiomyopathy. Radiology 2022;302:298-306. Go to original source... Go to PubMed...
    106. Yang S, Zhao K, Yang K, et al. Subendocardial Involvement as an Underrecognized LGE Subtype Related to Adverse Outcomes in Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging 2023;16:1163-1177. Go to original source... Go to PubMed...
    107. Briasoulis A, Mallikethi-Reddy S, Palla M, et al. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart 2015;101:1406-1411. Go to original source... Go to PubMed...
    108. Freitas P, Ferreira AM, Arteaga-Fernández E, et al. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death. J Cardiovasc Magn Reson 2019;21:50. Go to original source... Go to PubMed...
    109. Mahrholdt H, Seitz A. Refining the Prognostic Value of LGE in Hypertrophic Cardiomyopathy: Presence, Extent, and Location-What's Next? JACC Cardiovasc Imaging 2023;16:1178-1180. Go to original source... Go to PubMed...
    110. Diao K, Yang Z, Xu H, et al. Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysis. J Cardiovasc Magn Reson 2016;18:1-11. Go to original source... Go to PubMed...
    111. Avanesov M, Münch J, Weinrich J, et al. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR. Eur Radiol 2017;27:5136-5145. Go to original source... Go to PubMed...
    112. Li Y, Liu X, Yang F, et al. Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy. Eur Radiol 2021;31:4557-4567. Go to original source... Go to PubMed...
    113. Gommans DHF, Cramer GE, Bakker J, et al. High T2-weighted signal intensity for risk prediction of sudden cardiac death in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging 2018;34:113-120. Go to original source... Go to PubMed...
    114. Siontis KC, Ommen SR, Geske JB. Art and science of risk stratification of sudden cardiac death in hypertrophic cardiomyopathy: Current state, unknowns, and future directions. Prog Cardiovasc Dis 2023;80:25-31. Go to original source... Go to PubMed...
    115. Tower-Rader A, Mohananey D, To A, et al. Prognostic Value of Global Longitudinal Strain in Hypertrophic Cardiomyopathy: A Systematic Review of Existing Literature. JACC Cardiovasc Imaging 2019;12:1930-1942. Go to original source... Go to PubMed...
    116. Lee HJ, Kim HK, Lee SC, et al. Performance of 2020 AHA/ACC HCM Guidelines and Incremental Value of Myocardial Strain for Predicting SCD. JACC Asia 2023;4:10-22. Go to original source... Go to PubMed...
    117. Negri F, Muser D, Driussi M, et al. Prognostic role of global longitudinal strain by feature tracking in patients with hypertrophic cardiomyopathy: The STRAIN-HCM study. Int J Cardiol 2021;345:61-67. Go to original source... Go to PubMed...
    118. Ko WY, Siontis KC, Attia ZI, et al. Detection of Hypertrophic Cardiomyopathy Using a Convolutional Neural Network-Enabled Electrocardiogram. J Am Coll Cardiol 2020;75:722-733. Go to original source... Go to PubMed...
    119. Tison GH, Zhang J, Delling FN, et al. Automated and Interpretable Patient ECG Profiles for Disease Detection, Tracking, and Discovery. Circ Cardiovasc Qual Outcomes 2019;12:e005289. Go to original source... Go to PubMed...
    120. Pičulin M, Smole T, ®unkovič B, et al. Disease Progression of Hypertrophic Cardiomyopathy: Modeling Using Machine Learning. JMIR Med Inform 2022;10:e30483. Go to original source... Go to PubMed...
    121. Zhao K, Zhu Y, Chen X, et al. Machine Learning in Hypertrophic Cardiomyopathy: Nonlinear Model From Clinical and CMR Features Predicting Cardiovascular Events. JACC Cardiovasc Imaging. 2024;17:880-893. Go to original source... Go to PubMed...
    122. Finocchiaro G, Radaelli D, D'Errico S, et al. Sudden Cardiac Death Among Adolescents in the United Kingdom. J Am Coll Cardiol 2023;81:1007-1017. Go to original source... Go to PubMed...
    123. Kim JH, Martinez MW, Guseh JS, et al. A contemporary review of sudden cardiac arrest and death in competitive and recreational athletes. Lancet 2024;404:2209-2222. Go to original source... Go to PubMed...
    124. Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009;119:1085-1092. Go to original source... Go to PubMed...
    125. Petek BJ, Churchill TW, Moulson N, et al. Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study. Circulation 2024;149:80-90. Go to original source... Go to PubMed...
    126. Corrado D, Basso C, Pavei A, et al. Trends in Sudden Cardiovascular Death in Young Competitive Athletes After Implementation of a Preparticipation Screening Program. JAMA 2006;296:1593-1601. Go to original source... Go to PubMed...
    127. Steinvil A, Chundadze T, Zeltser D, et al. Mandatory Electrocardiographic Screening of Athletes to Reduce Their Risk for Sudden Death: Proven Fact or Wishful Thinking? J Am Coll Cardiol 2011;57:1291-1296. Go to original source... Go to PubMed...
    128. Pelliccia A, Day S, Olivotto I. Leisure-time and competitive sport participation: a changing paradigm for HCM patients. Eur J Prev Cardiol 2023;30:488-495. Go to original source... Go to PubMed...
    129. Lampert R, Ackerman MJ, Marino BS, et al. Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol 2023;8:595-605. Go to original source... Go to PubMed...
    130. Malhotra A, Dhutia H, Finocchiaro G, et al. Outcomes of Cardiac Screening in Adolescent Soccer Players. N Engl J Med 2018;379):524-534. Go to original source... Go to PubMed...
    131. Lampert R, Chung EH, Ackerman MJ, et al. 2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to play. Heart Rhythm 2024;21:e151-e252. Go to original source... Go to PubMed...
    132. Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease: The Task Force on sports cardiology and exercise in patients with cardiovascular disease of the European Society of Cardiology (ESC). Eur Heart J 2021;42:17-96. Go to original source... Go to PubMed...
    133. Basu J, Nikoletou D, Miles C, et al. High intensity exercise programme in patients with hypertrophic cardiomyopathy: a randomized trial. Eur Heart J 2025;46:1803-1815. Go to original source... Go to PubMed...
    134. Lee JM, Park H, Song JE, et al. The impact of cardiopulmonary exercise-derived scoring on prediction of cardio-cerebral outcome in hypertrophic cardiomyopathy. PLoS One 2022;17:e0259638. Go to original source... Go to PubMed...
    135. Francia P, Ziacchi M, Adduci C, et al. Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator. EP Europace 2023;25:euad270. Go to original source... Go to PubMed...
    136. Scherer E, Phelan D, Maron BJ, et al. PO-06-188 International Experience of Subcutaneeous Implanted Cardiovascular Defibrillators in Hypertrophic Cardiomyopathy. Heart Rhythm 2025;22:S715. Go to original source...
    137. Rella V, Maurizi N, Bernardini A, et al. Candidacy and long-term outcomes of subcutaneous implantable cardioverter-defibrillators in current practice in patients with hypertrophic cardiomyopathy. Int J Cardiol 2024;409:132202. Go to original source... Go to PubMed...
    138. Monkhouse C, Malcolmson J, Malcolmson J, et al. Evaluating subcutaneous implantable cardioverter defibrillators in hypertrophic cardiomyopathy: fewer complications without increased therapies. EP Europace 2025;27(Suppl.1):5-8. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes